You Asked the Internet About GLP-1s: Here's What It Couldn't Tell You
A guide to deciding, starting, affording, and living with the most talked-about diabetes medications in a generation. From someone who takes one.
Let me guess how you got here. You asked Google or a chatbot something like “Should I take Ozempic?” or “Mounjaro side effects.” You got a competent answer. It explained what GLP-1 medications are, listed the side effects, told you to talk to your doctor, and left you exactly where you started: alone with the actual decision.
If you want to know what comes after the definition, this article is for you. I am not going to explain what a gut hormone is for six paragraphs. I am going to walk you through the four moments that matter: deciding, the first eight weeks, the costs, and the long haul. And I am going to tell you what I would tell my own family, because I am not writing about diabetes from the outside. I live with it, and I take one of these medications myself.
It’s important to note that GLP-1s are not currently approved for type 1 diabetes, though they are being increasingly studied and some people use them off-label. Much of what follows may still apply to you. There is also new expert guidance specifically for people with type 1, which I will come back to at the end, because diaTribe helped write it.
Over the last decade, I put on about 25 extra pounds and was eventually diagnosed with type 2 diabetes. When my doctor sat me down to talk through my options, I leapt at the chance to take a medication that could lower my blood sugar, help me lose weight, and possibly reduce my risk of heart and kidney disease. Here is why.
The honest version of what these drugs do
GLP-1 receptor agonists help you feel full, eat less, and regulate blood sugar after meals. The best-known names are Ozempic, Wegovy, Mounjaro, and Zepbound, among several others.
A word on the names, because they trip everyone up: Ozempic and Wegovy contain the same active ingredient, semaglutide. Mounjaro and Zepbound also contain the same active ingredient, tirzepatide. This matters more than it sounds, because your insurance may cover one brand but not the other for the same active drug. It is worth asking about by name.
In large clinical trials, these medications lower A1C by roughly 1 to 2 percentage points and reduce body weight by 10-20% or more, depending on which drug and what dose. Several have shown protection for the heart, and semaglutide has shown benefits for the kidneys. For many of us with diabetes, those protective benefits may be the bigger story.
But here is the part the clinical trials could not really measure: the silence.
So many people I have talked with describe the same thing. The constant mental chatter about food simply gets quieter. There is even a name for it: food noise.
Before I started, I did not realize how much energy I spent thinking about food. Not eating it. Thinking about it. What was for dinner. Whether I should have dessert. Whether I was really hungry. Whether I had already messed up my diet and might as well keep going.
The biggest surprise was not that I ate less. It was how much quieter all of that became. If you have never lived with food noise, that paragraph may not mean much. If you have, it may be the most important one in this article.
How to decide: the questions that matter
“Should I take a GLP-1?” is not really one question. It’s five for your doctor and, honestly, a sixth one for yourself. Bring the first five to your next appointment instead of a printout of a drug ad.
1. What is my primary goal? Lowering your A1C, losing weight, and protecting your heart and kidneys can all be on the table, but name your priority out loud. It can change the direction of the conversation about which drug to take.
2. Is this drug safe? People with a personal or family history of medullary thyroid cancer, or a condition called MEN2, should not take these drugs. A history of pancreatitis or gallbladder disease deserves a direct conversation, too.
3. Am I ready for the adjustment period? Plan on roughly eight weeks for your stomach to figure out how to deal with the drug. Most people get through it. Some do not, and stopping is not failure. It’s just information.
4. Can I afford month seven, not just the first month? If you have a coupon that makes the first month cheap, that may not help you in month seven. Ask if your insurer will cover some of the costs and what they require before approving payment.
5. What happens to my other medications? If you take insulin or a sulfonylurea, adding a GLP-1 can increase the risk of low blood sugar unless you adjust your dose. This is a must-have, day-one conversation, not a week-three decision to figure it out.
And the sixth, the one to ask yourself: how do I feel about taking a medication for this? Many people worry they are taking the “easy way” out or worry about judgment from family, friends, or strangers online. I understand those worries. But diabetes and obesity are chronic conditions, not character flaws.
Getting started: the first eight weeks, honestly
Doctors start these drugs at a low dose and then raise the dose slowly over time, because the most common side effects, nausea, constipation, and sometimes vomiting or diarrhea, are mostly your digestive system adapting. We’ve learned a lot about making this easier, and very little of it is on the drug label:
Eat smaller meals and stop when you start to feel full. That feeling arrives earlier now, and it means something.
Put protein first on the plate. Protein protects your muscles while you lose weight, which in some ways matters more than the number on the scale.
Greasy and fried foods are the nausea triggers people mention the most. You do not have to swear them off forever, maybe just the first few weeks.
Drink water like it is your job. Dehydration sneaks up when you are eating less. Seriously, drink water.
Move your body and lift something a few times a week. Weight loss should be mostly fat, not muscle mass, and resistance exercise can help.
Call your care team, do not wait, if you have severe stomach pain that will not pass, vomiting you cannot stay ahead of, or signs of dehydration like dizziness and very dark urine. Problems like pancreatitis are rare, but they can happen.
There were a few things that stood out and surprised me when I first started a GLP-1. One benefit was that the food noise got quieter. I found that the first few weeks were harder than the months that followed, and that the insurance paperwork can be as frustrating as the side effects. In terms of goals, weight loss mattered, but the chance to protect my heart and kidneys came to matter more. I also learned that I needed to prioritize protein and exercise to stay strong while losing weight.
The money
In the United States, list prices for these medications can run you near four figures a month before insurance. Whether you pay that much depends on your coverage, prior authorization, and savings programs, which is to say it depends on paperwork and your persistence. Three things I want you to know:
A denial is the beginning, not the end. Insurers often deny first requests and approve appeals, especially when your clinician documents medical need. Ask your care team if they will file an appeal. The answer can be yes.
Manufacturer savings programs are real but have conditions. Eligibility usually depends on having commercial insurance, and the terms can change over time.
Be careful with cheap online versions. If a price looks too good to be true from a website you have never heard of, trust that instinct. Be especially cautious about medications sold through websites that do not require a prescription. I stick with the FDA-approved versions since safety comes first for me.
The long haul
These are long-term medications for a long-term condition. In the studies I’ve read where people stopped taking a GLP-1, most of them regained much of the weight within a year, and their blood sugar benefits faded too.
That is not weakness. That is biology, the same reason nobody calls it failure when blood pressure climbs after you stop a blood pressure pill. That doesn't mean nobody can successfully come off these medications. Some people do. But I think most people should go into treatment assuming this is a long-term decision.
People often ask whether they will need to stay on these medications forever. I understand the question. I asked it too. But over time, I found myself asking a different one: if this medication helps me lose weight, keeps it off, protects my heart, and improves my blood sugar, and it is safe for me, why would I stop?
We do not ask that about blood pressure medications or cholesterol medications. Yet somehow, we ask it constantly about diabetes and obesity treatments.
The loudest voices online will tell you these drugs are the easy way out. Here is what I think, stated plainly: there is no easy way out of a chronic disease, and there is no prize for suffering more than you have to. Taking a medication that quiets food noise, lowers your A1C, helps you lose weight, and may protect your heart and your kidneys is not cheating. It’s a treatment.
I needed help losing the extra weight and getting my blood glucose back toward where it was when I was younger. And because my grandfather, who also had diabetes, died of a heart attack at 64, the cardiovascular protection these medications may offer matters to me more than I can easily put into words.
GLP-1 medicines for type 1 diabetes
Earlier this year, diaTribe convened a global panel of diabetes experts to write the first international consensus on the safe use of GLP-1 medications in type 1 diabetes, an area where people have been using these drugs off-label without much formal guidance. My colleague Julie Heverly and I were among the co-authors, there to represent the patient advocacy perspective alongside leading clinicians from around the world. I am not telling you this to boast. I am telling you because it is the clearest example I have of what diaTribe is for: making sure the patient voice is in the room when the guidance gets written.
Final note (and my stake in it)
This drug class changes every few months: new trial results, new shortages, new coverage rules, new options. Here at diaTribe, we read all of it. Many of us live with diabetes ourselves, and we send our readers a daily, short version of what changed and what to do about it. If this article gave you something a search result could not, that is what our newsletter does every day. Subscribe for free to our newsletters at diatribe.org/subscribe.
A note on independence: diaTribe is a nonprofit organization, and this article was written and edited without input or review from any drug manufacturer. I take a GLP-1 drug, and I was an unpaid co-author of the type 1 consensus mentioned above. I named specific brands only to be useful, not because any company asked or paid me to.
diaTribe does not provide medical diagnosis, advice, or treatment. Talk with your care team before starting, stopping, or changing any medication.
Learn more about GLP-1-based medications here: